Updates are available Correction dated 2024-03-18
Click to view Correction: https://doi.org/10.1007/s00198-024-07048-x
-
Authors
Khan, Aliya A. http://orcid.org/0000-0003-3733-8956
Brandi, Maria Luisa http://orcid.org/0000-0002-8741-0592
Rush, Eric T. http://orcid.org/0000-0002-8147-7315
Ali, Dalal S. http://orcid.org/0000-0002-5378-5548
Al-Alwani, Hatim http://orcid.org/0000-0001-9036-7903
Almonaei, Khulod http://orcid.org/0000-0002-7293-2654
Alsarraf, Farah http://orcid.org/0000-0001-9426-9702
Bacrot, Severine http://orcid.org/0000-0001-9311-5664
Dahir, Kathryn M. http://orcid.org/0000-0002-9980-9138
Dandurand, Karel http://orcid.org/0000-0003-1759-8419
Deal, Chad http://orcid.org/0000-0002-7591-4718
Ferrari, Serge Livio http://orcid.org/0000-0002-1372-4417
Giusti, Francesca http://orcid.org/0000-0002-8576-9606
Guyatt, Gordon http://orcid.org/0000-0003-2352-5718
Hatcher, Erin http://orcid.org/0000-0002-3638-4742
Ing, Steven W. http://orcid.org/0000-0002-4343-6723
Javaid, Muhammad Kassim http://orcid.org/0000-0001-7985-0048
Khan, Sarah http://orcid.org/0000-0003-3604-303X
Kocijan, Roland http://orcid.org/0000-0002-2618-1546
Linglart, Agnes http://orcid.org/0000-0003-3455-002X
M’Hiri, Iman http://orcid.org/0000-0002-6151-3366
Marini, Francesca http://orcid.org/0000-0002-3678-4922
Nunes, Mark E. http://orcid.org/0000-0001-6338-1726
Rockman-Greenberg, Cheryl http://orcid.org/0000-0002-4741-8442
Roux, Christian http://orcid.org/0000-0002-9598-9346
Seefried, Lothar http://orcid.org/0000-0003-1154-3388
Simmons, Jill H. http://orcid.org/0000-0002-4189-6718
Starling, Susan R. http://orcid.org/0000-0003-1813-5600
Ward, Leanne M. http://orcid.org/0000-0003-1557-9185
Yao, Liang http://orcid.org/0000-0003-4068-3136
Brignardello-Petersen, Romina http://orcid.org/0000-0002-6010-9900
Lewiecki, E. Michael http://orcid.org/0000-0003-2026-9587
-
Funding
Funding for this research was provided by:
Alexion Pharmaceuticals
International Osteoporosis Foundation
- License Information
-
More Information
Article History
Received: 29 December 2022
Accepted: 23 June 2023
First Online: 20 November 2023
Change Date: 18 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00198-024-07048-x
Declarations
:
: These papers are retrospective reviews and did not require ethics committee approval.
: AAK has received research grants from Alexion, Amgen, Ascendis, Chugai, Radius, Takeda, and Ultragenyx and is on the advisory board for Amgen, Amolyt, and Takeda. MLB has received honoraria from Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, and UCB; grants and/or speaker for Abiogen, Alexion, Amgen, Bruno Farmaceutici, Echolight, Eli Lilly, Kyowa Kirin, SPA, Theramex, and UCB; Consultant for Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, and UCB. ETR has consulted for, received honoraria from, and has research supported by Alexion Pharmaceuticals, AstraZeneca Rare Disease. SB has received advisory board participation from Alexion. KMD has received research grants and honoraria from Alexion. CD serves as an investigator, consultant, and speaker for Amgen; investigator for Radius; speaker for Alexion. SWI has received grant funding and ad hoc advisory board participation from Alexion Pharmaceuticals. MKJ has received honoria and grants from UCB, Amgen, Kyowa Kirin, Sanofi, Besin Healthcare, and Abbvie. RK is a speaker and has received research funding from Alexion, AstraZeneca Rare Disease. AL is a consultant for and has received research funding and honoraria from Alexion. MEN serves as a non-paid consultant (fee equivalent donated to 501(c)3 patient advocacy groups) for Alexion. CRG is a member of the Scientific Advisory Board of the HPP Global Patient Registry sponsored by Alexion AstraZeneca Rare Disease. She has had received honoraria for participation on this Board and has also received honoraria for select Alexion-sponsored presentations.CR has received research grants and honoraria from Alexion, Kyowa Kirin, and Regeneron. LS has received honoraria and grants from Alexion, Amgen, Chiesi, KyowaKirin, Novartis, Theramex, and UCB. JHS serves as an Investigator and consultant for Alexion. SRS has received honoraria from and has research supported by Alexion Pharmaceuticals, AstraZeneca Rare Disease. LMW serves as a consultant to Alexion. EML serves as an investigator, consultant, and speaker for Amgen; investigator for Radius; speaker for Alexion. DSA, HA, KA, FA, KD, SLF, FG, GG, EH, SK, IM, FM, LY, RBP declare no conflict of interest.
